Flindr Therapeutics (formerly known as Immagene) was founded in 2020, as a spin-out of the Netherlands Cancer Institute and Oncode Institute, with the aim of developing next-generation first-in-class small molecule therapeutics for the precision treatment of cancer. Based on seminal findings which emerged from the labs of Daniel Peeper and Christian Blank, Flindr Therapeutics embarked on a drug discovery campaign against novel targets in hard-to-treat tumor indications.
Daniel Peeper: “I am very excited about this investment in Flindr Therapeutics. Among other activities, it allows the company to advance its lead program — the development of a first-in-class small molecule inhibitor of RNF31. This protein was previously identified in my laboratory in a genome-wide screen for new cancer therapeutic targets. It is gratifying to witness this fundamental discovery translate into the development of a novel anticancer drug.”
Congratulations to the entire Flindr team for their dedication and hard work, resulting in this important achievement!